


## CLAIMS

What is claimed is:

1. A compound of Formula (I)



(I)

wherein

R<sup>1</sup> is hydrogen or (C<sub>1</sub>-C<sub>4</sub>)alkyl;

- R<sup>2</sup> is hydrogen, -C(O)R<sup>2a</sup>, -C(O)-(CH<sub>2</sub>)<sub>n</sub>-R<sup>2b</sup>, or -(CH<sub>2</sub>)<sub>m</sub>-R<sup>2c</sup>, where n is 0, 1 or 2, m is 0, 1, 2 or 3, R<sup>2a</sup> is (C<sub>1</sub>-C<sub>4</sub>)alkyl or halo-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl, and R<sup>2b</sup> and R<sup>2c</sup> are -NH(C<sub>1</sub>-C<sub>4</sub>)alkyl, -N((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>, pyridinyl, hydroxy(C<sub>1</sub>-C<sub>4</sub>)alkyl, phenyl, or piperidinyl;

R<sup>3</sup> is (C<sub>1</sub>-C<sub>6</sub>)alkyl; and

X is carbonyl or methylene;

- a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

2. The compound of Claim 1 wherein X is carbonyl; a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

3. The compound of Claim 1 wherein X is methylene; a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

4. The compound of Claim 2 or 3 wherein  $R^2$  is  $-C(O)-(CH_2)_n-R^{2b}$ ; a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

5

5. The compound of Claim 4 wherein  $R^{2b}$  is pyridinyl; a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

10

6. The compound of Claim 5 wherein  $R^{2b}$  is 3-pyridinyl or 4-pyridinyl; a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

15

7. The compound of Claim 2 or 3 wherein  $R^2$  is  $-(CH_2)_m-R^{2c}$ ; a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

20

8. The compound of Claim 7 wherein  $R^{2c}$  is  $-NH(C_1-C_4)alkyl$  or  $-N((C_1-C_4)alkyl)_2$ ; a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

25

9. The compound of Claim 1 selected from the group consisting of  
9-amino-5-ethyl-5H-phenanthridin-6-one;  
9-amino-5-isopropyl-5H-phenanthridin-6-one;  
9-Amino-5-isobutyl-5H-phenanthridin-6-one;  
N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2,2,2-trifluoroacetamide;  
N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2-pyridin-4-yl-acetamide;

30

2-dimethylamino-N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-  
acetamide;

N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-3-piperidin-1-yl-  
propionamide;

5        2-dimethylamino-N-(5-isopropyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-  
acetamide;

N-(5-isopropyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2-pyridin-4-yl-  
acetamide;

10       N-(5-isopropyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-3-piperidin-1-yl-  
propionamide;

N-(5-isopropyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2-pyridin-3-yl-  
acetamide;

N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2-hydroxy-  
isobutyramide;

15       N-(5-ethyl-5,6-dihydro-phenanthridin-9-yl)-2,2,2-trifluoro-acetamide;  
9-(3-dimethylamino-propylamino)-5-ethyl-5H-phenanthridin-6-one; and  
9-benzylamino-5-ethyl-5H-phenanthridin-6-one;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said  
compound or said salt.

20

10.    The compound of Claim 4 selected from the group consisting of  
N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2,2,2-trifluoro-  
acetamide;

25       N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2-pyridin-4-yl-  
acetamide;

2-dimethylamino-N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-  
acetamide;

N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-3-piperidin-1-yl-  
propionamide;

2-dimethylamino-N-(5-isopropyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-acetamide;

N-(5-isopropyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2-pyridin-4-yl-acetamide;

5 N-(5-isopropyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-3-piperidin-1-yl-propionamide;

N-(5-isopropyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2-pyridin-3-yl-acetamide;

10 N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2-hydroxy-isobutyramide; and

N-(5-ethyl-5,6-dihydro-phenanthridin-9-yl)-2,2,2-trifluoro-acetamide;  
a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

15 11. The compound of Claim 7 selected from the group consisting of 9-benzylamino-5-ethyl-5H-phenanthridin-6-one; and 9-(3-dimethylamino-propylamino)-5-ethyl-5H-phenanthridin-6-one;  
a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

20 12. A pharmaceutical composition comprising a compound of any one of the preceding claims and a pharmaceutically acceptable excipient, diluent, or carrier.

25 13. The pharmaceutical composition of Claim 12 further comprising at least one additional pharmaceutical agent.

14. The pharmaceutical composition of Claim 13 wherein said at least one additional pharmaceutical agent is selected from the group consisting of an  
30 anti-obesity agent, an anorectic agent, a sorbitol dehydrogenase inhibitor, a

aldose reductase inhibitor, a glycogen phosphorylase inhibitor, a cholinomimetic agent, an anti-depressant, an antianxiolytic agent, and a typical or atypical antipsychotic agent.

- 5           15.    A method for treating a disease, condition or disorder modulated  
by a NPY-5 receptor antagonist in animals comprising the step of administering  
to an animal in need of such treatment a therapeutically effective amount of a  
compound of Claim 1, a pharmaceutically acceptable salt thereof, a prodrug of  
said compound or said salt, or a solvate or hydrate of said compound, said salt  
10   or said prodrug.

16.    The method of Claim 15 wherein said disease, condition or  
disorder is obesity, a feeding disorder, seizures, anxiety, diabetes,  
hypertension, hyperlipidemia, pancreatic or breast cancer, nasal congestion,  
15   female or male sexual dysfunction, congestive heart failure, an intestinal  
dysfunction, or a psychiatric disorder.